SG Americas Securities LLC Cuts Stock Holdings in Haemonetics Co. (NYSE:HAE)

SG Americas Securities LLC lessened its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 48.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,832 shares of the medical instruments supplier's stock after selling 9,414 shares during the period. SG Americas Securities LLC's holdings in Haemonetics were worth $790,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its stake in shares of Haemonetics by 14.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier's stock valued at $16,354,000 after purchasing an additional 24,394 shares in the last quarter. Quantbot Technologies LP grew its holdings in Haemonetics by 2,101.6% during the 1st quarter. Quantbot Technologies LP now owns 14,068 shares of the medical instruments supplier's stock worth $1,201,000 after acquiring an additional 13,429 shares during the last quarter. Silvercrest Asset Management Group LLC acquired a new position in Haemonetics in the 1st quarter valued at approximately $38,706,000. Allspring Global Investments Holdings LLC raised its stake in shares of Haemonetics by 132.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier's stock valued at $42,930,000 after acquiring an additional 286,897 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Haemonetics by 38.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier's stock worth $48,006,000 after purchasing an additional 156,665 shares during the period. Institutional investors own 99.67% of the company's stock.

Insiders Place Their Bets

In related news, insider Stewart W. Strong sold 4,312 shares of the company's stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the sale, the insider now owns 18,196 shares in the company, valued at approximately $1,658,565.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.80% of the company's stock.

Analyst Upgrades and Downgrades

HAE has been the subject of several analyst reports. Barrington Research reaffirmed an "outperform" rating and set a $108.00 target price on shares of Haemonetics in a research report on Monday, September 23rd. Citigroup cut their price objective on Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a research note on Thursday, August 22nd. Bank of America initiated coverage on shares of Haemonetics in a report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price target for the company. CL King initiated coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a "buy" rating and a $116.00 price objective on the stock. Finally, JMP Securities reiterated a "market outperform" rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $106.14.

Haemonetics Stock Up 0.7 %

Shares of HAE traded up $0.52 during trading hours on Friday, hitting $74.97. The stock had a trading volume of 711,162 shares, compared to its average volume of 541,931. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.97. The firm has a market capitalization of $3.82 billion, a P/E ratio of 32.74, a price-to-earnings-growth ratio of 1.19 and a beta of 0.30. The firm has a 50 day simple moving average of $76.33 and a 200-day simple moving average of $83.88. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The company's revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 EPS. Sell-side analysts predict that Haemonetics Co. will post 4.57 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.